Exozymes annual free cash flow
2022
2023
2024
2025
Exozymes Free Cash Flow (FCF) History (EXOZ)
Exozymes reported −$6.7M in free cash flow for fiscal 2025, an increase of $2.2M from the previous fiscal year.
View full Exozymes company overviewExozymes free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.7M | $2.2M | — | — |
| 2024 | 2024-12-31 | −$8.9M | −$7.4M | — | — |
| 2023 | 2023-12-31 | −$1.5M | −$26,503 | — | −2097.34% |
| 2022 | 2022-12-31 | −$1.4M | — | — | — |
Exozymes quarterly free cash flow
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.6M | −$51,707 | — | — |
| Q1 2026 | 2026-03-31 | −$1.6M | −$417,466 | — | — |
| Q4 2025 | 2025-12-31 | −$2.0M | $3.9M | — | — |
| Q3 2025 | 2025-09-30 | −$1.9M | −$1.3M | — | — |
| Q2 2025 | 2025-06-30 | −$1.6M | $986,463 | — | — |
| Q1 2025 | 2025-03-31 | −$1.2M | −$1.3M | — | — |
| Q4 2024 | 2024-12-31 | −$5.9M | — | — | — |
| Q3 2024 | 2024-09-30 | −$541,524 | — | — | — |
| Q2 2024 | 2024-06-30 | −$2.6M | — | — | — |
| Q1 2024 | 2024-03-31 | $132,391 | — | — | — |
Exozymes free cash flow growth trends
Exozymes's latest reported quarter, Q2 2026, generated −$1.6M in free cash flow, a decrease of $51,707 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Exozymes source filings ↗Community posts
eXoZymes selects Curia to scale up its NCT manufacturing process
eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and pro ...